These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 29274618)

  • 1. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
    J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
    Chan BM; Hochster HS; Lenz HJ
    Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
    Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
    Mayer RJ; Van Cutsem E; Falcone A; Yoshino T; Garcia-Carbonero R; Mizunuma N; Yamazaki K; Shimada Y; Tabernero J; Komatsu Y; Sobrero A; Boucher E; Peeters M; Tran B; Lenz HJ; Zaniboni A; Hochster H; Cleary JM; Prenen H; Benedetti F; Mizuguchi H; Makris L; Ito M; Ohtsu A;
    N Engl J Med; 2015 May; 372(20):1909-19. PubMed ID: 25970050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
    Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
    BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
    Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
    Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
    Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
    Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
    Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
    JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.